Delivering Innovative Renal
and Vascular Therapies
Developing novel, first-in-class pharmaceuticals to address the
medical needs of patients with renal and vascular diseases
Addressing Vascular Access
Failure in Hemodialysis
Improving vascular access outcomes would provide a
lasting benefit to hemodialysis patients
Learn More
About PRT-201
An investigational drug for the reduction of vascular
access failure for patients receiving hemodialysis
We are a biopharmaceutical company developing novel, first-in-class pharmaceuticals for patients with renal and vascular diseases. Our ongoing Phase 3 clinical trial is evaluating whether a single treatment of PRT-201 can reduce vascular access failure, one of the most serious problems experienced by patients with chronic kidney disease (CKD) undergoing hemodialysis. PRT-201 is an investigational drug that may inhibit neointimal hyperplasia, the growth of tissue inside blood vessels that can result in vessel narrowing and reduced blood flow. PRT-201 has received fast track and orphan drug designations for hemodialysis vascular access indications.
